Skip to main content
Clinical Trials/TCTR20190705002
TCTR20190705002
Enrolling By Invitation
未知

Comparison of the clinical efficacy of subcutaneous versus oral administration of methotrexate in patients with psoriasis vulgaris

Faculty of Medicine0 sites80 target enrollmentJuly 5, 2019

Overview

Phase
未知
Intervention
Not specified
Conditions
psoriasis vulgaris
Sponsor
Faculty of Medicine
Enrollment
80
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 5, 2019
End Date
September 30, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Faculty of Medicine

Eligibility Criteria

Inclusion Criteria

  • Entry criteria require a clinical diagnosis of psoriasis vulgaris in patients who had
  • the Psoriasis Area Severity Index (PASI) score \> 10 or body surface area (BSA) involvement \>10% or who had PASI score \<10 or BSA \< 10% but did not respond to topical treatment and being at least 18 years of age

Exclusion Criteria

  • Exclusion criteria include pregnant or lactating women, known hypersensitivity to methotrexate, patients with malignancy or HIV\-infection or hepatitis B or C infection, tuberculosis, and abnormal liver or kidney or hematologic function. All patients will have a 12\-week washout of any systemic therapies including systemic corticosteroid, methotrexate, cyclosporine, acitretin, other immunosuppressive drugs, biologics and phototherapy for psoriasis prior to receiving the study drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials